Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1800 participants.
Also called NCT01341353
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,800 participants
- Sponsor
- Registry
-
NCT01341353
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01341353. Non-randomized; no masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
- Condition
- Atrial Fibrillation
- Intervention (Procedure)
- catheter ablation
- Intervention (Drug)
- Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
- Lead sponsor
- Wuhan University
- Collaborator
- Capital Medical University
- Collaborator
- Peking Union Medical College
- Collaborator
- Guangdong Provincial People's Hospital
- Collaborator
- Nanjing Medical University
- Collaborator
- West China Hospital
- Collaborator
- Dalian Medical University
- Collaborator
- Shanghai Chest Hospital
Record details
- Record id
cardio:ct-nct01341353- Content hash
52465f84d7c87d159aa349f261e8526a72d56b7477bbd025bd87519fda91a8e5